Yazar "Budak, Beyhan" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antibody responses post-booster covid-19 vaccination: insights from a single-center prospective cohort study(2024) Dinç, Harika Öykü; Can, Günay; Budak, Beyhan; Daşdemir, Ferhat Osman; Keskin, Elif; Kırkoyun Uysal, Hayriye; Aydoğan, Okan; Balkan, İlker İnanç; Karaali, Rıdvan; Ergin, Sevgi; Saltoğlu, Neşe; Kocazeybek, BekirThe study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different vaccination schemes for booster doses. Anti-spike/RBD-IgG and neutralizing antibody levels were measured 28 days after the booster dose vaccination upon their consent. There is no significant difference between median antibody titers detected according to different vaccination schemes. SARS-CoV-2 neutralizing antibody inhibition percentages were detected significantly higher in serum samples before and after the last booster dose in 2 BNT162b2+1 BNT162b2(99.42 %), 2 BNT162b2 + 2 BNT162b2(99.42 %), and 2 BNT162b2 + 3 BNT162b2(99.42 %) vaccination schemes (p = 0.004, p = 0.044, p = 0.002,respectively). The study indicated that a booster vaccination dose provides a high level of protection against severe COVID-19 and death. We think that the variant-specific pancoronavirus vaccines will be necessary to protect against breakthrough infections.Öğe Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs(Elsevier Inc., 2022) Saltoğlu, Neşe; Dinç, Harika Öykü; Balkan, İlker İnanç; Can, Günay; Özbey, Doğukan; Beytur, Ayşe Nur; Keskin, Elif; Budak, Beyhan; Aydoğan, Okan; Mete, Bilgül; Karaali, Rıdvan; Ergin, SevgiThe objective of our study was to evaluate the antibody responses of health care workers (HCWs) who were vaccinated with booster dose BNT162b2 6 months after 2 doses of the CoronoVac vaccine. The study included 318 HCWs vaccinated with inactive CoronaVac SARS-CoV-2 vaccine in 2 doses. Anti-spike/RBD IgG levels were measured immediately before and 1 month after the booster dose. In the sixth month after CoronaVac vaccination, the median of antibody levels of 1212.02 AU/ML, while it was 9283 AU/mL after BNT162b2 vaccination. IgG antibody titers of over 1050 AU/mL (which is equivalent to 1:80 dilution in the plaque reduction neutralization test) were detected in HCWs 15.09% and 97.8%, respectively. Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, especially in individuals with risk factors.Öğe Homologous or heterologous COVID-19 vaccine schemes: Comparison of immune responses and side effects(Elsevier Inc., 2023) Karaali, Rıdvan; Dinç, Harika Öykü; İnanç Balkan, İlker; Can, Günay; Keskin, Elif; Çolak, Hatice; Daşdemir, Ferhat Osman; Aydoğan, Okan; Budak, Beyhan; Yıldız Kaya, Sibel; Kocazeybek, Bekir; Saltoğlu, NeşeReal-life data are needed regarding the appropriate time and selection of vaccination strategies, homologous or heterologous. We aimed to compare neutralizing antibody levels and side effects in different vaccination schemes. The study included 310 Health Care Workers (HCWs) vaccinated with 5 different schemes. Antispike/RBD IgG levels were measured between 28 and 60 days after the last dose. Side effects in participants were recorded, and pharmacovigilance records were reviewed from the outpatient vaccine clinic. Mean age of the participants was 38 ± 11 years of whom 226 (72.9%) were female, and 84 (27.1%) were male. After booster doses, increasing antibody levels were detected in all groups. Mean antibody levels were detected to be statistically lower in 3 doses of inactivated vaccines group. The side effects were no significant difference between groups. Booster dose administration with mRNA vaccines stands out as the most accurate strategy for those at risk of contracting severe COVID-19 and HCWs caring for this population.Öğe Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: Booster required(Springer London Ltd, 2023) Balkan, İlker İnanç; Dinç, Harika Öykü; Can, Günay; Karaali, Rıdvan; Özbey, Doğukan; Çağlar, Bilge; Beytur, Ayşe Nur; Keskin, Elif; Budak, Beyhan; Aydoğan, Okan; Mete, Bilgül; Ergin, Sevgi; Kocazeybek, Bekir; Saltoğlu, NeşeAims Despite high vaccination rates, increasing case numbers continue to be reported with the identification of new variants of concern, and the issue of durability of the vaccine-induced immune response remains hot topic. Real-life data regarding time-dependent immunogenicity of inactivated COVID-19 vaccines are scarce. We aimed to investigate the changes in the antibody at the different times after the second dose of the CoronaVac vaccine. Methods The study included 175 HCWs vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses. Anti-spike/RBD IgG levels were measured first, third, and sixth months after the second dose. Chemiluminescent microparticle immunoassay (IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test, was used. Results Mean age of the participants was 38 +/- 11.23 years (range between 22 and 66) of whom 119 (63.9%) were female, and 56 (32%) were male. Dramatic reductions were demonstrated in median antibody levels particularly in the infection-naive group, comprising 138 HCWs compared to those with prior history of COVID-19 infection (n = 37) (p < 0.001). There was no difference between the two groups in terms of age, gender, blood groups, BMI, and comorbid diseases. Conclusions While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly. The decrease was more rapid and significant in those with no history of prior COVID-19 infection. In this critical phase of the pandemic, where we are facing the dominance of the Omicron variant after Delta, booster doses have become vital.
